





MONITORING FRENCH WEST AFRICAN CONTRACPETIVE MARKETS USING IMS DATA





Denise L Harrison, MA, MBA
Office of Population and Reproductive Health, USAID
Peter Stephens, MA
IMS Health





EQUITY












The Value Of Market Data





IMS Health

2004-2014
REPRODUCTIVE HEALTH
SUPPLIES COALITION

D L Harrison, P Stephens October 23, 2014

- Founded in 1954
- Largest pharmaceutical market research group
 - Core methodology: invoice audits
- Over 100 countries covering private and public sectors, 100,000 data suppliers, 1 million products covered
 - Routine data collection in South Africa, French West Africa and North Africa
 - 2013 IMS White Paper: Africa A Ripe Opportunity
- Major source for pharmaceutical market data for governments, regulators (WHO and FDA) and industry

Partnering with Governments and **NGOs in Africa**



- MMV-IMS partnership since 2010 in Zambia and Uganda with the regulatory authorities and MoH in each country
- USAID Angola-DNME-IMS MoU (draft)

SENEGAL - Private Sector CYP 2011 - 2013



Method	CYP 2011	CYP 2012	CYP 2013	Percent growth
Injectables	5,807	5,597	5,579	-4%
Orals (exc progestin only)	29,026	27,312	33,453	15%
Emergency Contraceptives	5,360	6,135	7,024	31%
IUD with hormone		30	63	111%
TOTAL	40,192	39,073	46,119	15%

Source: © IMS Health. Not for re-use without permission of copyright holder

Summary of Senegal Private Sector



Social marketing and unsubsidized commercial contraceptives make up only 5% of estimated total CYPs in Senegal

Private sector CYP has growth by 15% from 2011 – 2013

mCPR has grown from 10% to 12% from 2005 to 2012 (track20.org)

Need to ensure private sector continues growing including unsubsidized private sector

66

The successful warrior is the average man, with laser-like focus

- Bruce Lee